Navigation Links
Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
Date:12/9/2008

icine, Hematology/Neurology, and Oncology. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and reported revenues in 2007 of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

Genzyme's press releases and other company information are available at www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States. Genzyme(R), Campath(R) and MabCampath(R) are registered trademarks of Genzyme Corporation. All rights reserved.

Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
3. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
4. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
5. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
6. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
7. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
8. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... ZURICH, Ill., Dec. 15 Fenwal Inc., a ... availability for patient care, reiterated its commitment to provide ... lifesaving blood products, despite a new lawsuit filed yesterday ... Fenwal® Alyx® system, introduced in 2003, is an advanced ... red cells from a single donor in about 30 ...
(Date:12/15/2009)... -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) ... 2009 special dividend payment of $1.67 per share to ... 1, 2009. With this payment, distributions to stockholders ... per share. In January 2010, the Company will ... the Company,s 2009 cash distributions and the allocation between ...
(Date:12/15/2009)... Champions Biotechnology, Inc . (OTC ... development of advanced preclinical platforms and tumor specific ... today announced its financial results for the second ... details of Company,s financial results are available in ... ,, Total revenues for the second quarter of ...
Breaking Medicine Technology:Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers 2Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers 3PDL BioPharma Completes December 15 Special Dividend Payment 2Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 5Cepheid Receives FDA Clearance for First On Demand Molecular Diagnostic Test for Clostridium difficile Infection 51429 1Cepheid Receives FDA Clearance for First On Demand Molecular Diagnostic Test for Clostridium difficile Infection 51429 2Cepheid Receives FDA Clearance for First On Demand Molecular Diagnostic Test for Clostridium difficile Infection 51429 3Cepheid Receives FDA Clearance for First On Demand Molecular Diagnostic Test for Clostridium difficile Infection 51429 4Cepheid Receives FDA Clearance for First On Demand Molecular Diagnostic Test for Clostridium difficile Infection 51429 5Spots Still Available to Run 2009 ING New York City Marathon With Team Reeve 51427 1Spots Still Available to Run 2009 ING New York City Marathon With Team Reeve 51427 2Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class 4717 1Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class 4717 2Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class 4717 3
... -, PHOENIX, Sept. 4 Zila, Inc.,s (Nasdaq: ... early detection of,abnormalities which can lead to oral cancer, ... II study of Cetuximab (ERBITUX(R)), a,leading cancer therapeutic for ... IMCL ) and distributed by Bristol-Meyers Squibb (NYSE:,BMY). ...
... Monte Carlo brings predictability to whole range ... of Phase II, III and ... Tourtellotte Solutions, a,global leader in off-the-shelf and custom supply ... today announced,the release of its tcVisualize(TM) 3.0 clinical trial ...
Other Medicine Technology:Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 2Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 3Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator 2
(Date:12/16/2009)... myopia now than in the ,70s, study finds , , ... more common in the United States than it was ... study shows. , Researchers compared National Health and Nutrition ... from 1971 to 1972 and from 8,339 black and ... 12 to 54 years old. , The prevalence of ...
(Date:12/16/2009)... earn a free 21-count one week trial bottle sample with purchase ... ... December 16, 2009 -- ImmuneResponse247.com announces a special ... Immune Response 247™ 6 Mushroom Formula , with the purchase ... 247™ 6 Mushroom Formula is packaged in FDA approved facilities and ...
(Date:12/16/2009)... proud to announce being presented with the Weatherhead 100 Upstart Award ... growing companies in Northeast Ohio and is a testament to hard ... , ... (PRWEB) December 16, 2009 -- Request A ... 100 Upstart Award on December 3, 2009. The Weatherhead 100 ...
(Date:12/16/2009)... the perfect gift to give that special woman who has everything? ... Esthetician Mary Schook introduces exceptional beauty products online while educating the ... ... (PRWEB) December 16, 2009 -- The holidays are rapidly ... special woman who has everything? Why stem cells, of course!, , ...
(Date:12/15/2009)... SUMMARY: The U.S. Senate today rejected ... Care Act that would have helped make prescription ... and legal importation of lower priced drugs from ... sponsored by Senators Dorgan, Snowe, McCain, Grassley and ... bring down the skyrocketing costs of prescription drugs. ...
Breaking Medicine News(10 mins):Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 2Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 4Health News:Request A Test Receives Weatherhead 100 Upstart Award 2Health News:New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything 2Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 2Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 3
... to the issue of self harm. Self-Harm is most often ... support, help and above all, understanding. According to a recent ... to help a person who self-harms. ,The "see ... to the fore - that nearly 41% of adults ...
... has now established that a delayed-release stimulant, used for ... with less abuse, when compared to other stimulant drugs//. ... an oral formulation have not been reported to produce ... results of the study can be found in the ...
... is a major cause of depression and Alzheimer's disease in ... which shrinks in old age resulting in depression and Alzheimer's ... develop new treatments for Alzheimer’s disease. ,The shrinkage ... cortex result in the release of high levels of stress ...
... Paris: The French government is bracing itself to tackle a ... called the Chikungunya Fever, known to be spread by mosquitoes// ... poses a risk of entering into France. ,According ... infected one fifth of La Reunion's population , and many ...
... P's and Q's, trim your hair, cut your nails, polish your ... women, no gaudy saris please //-- just some of the do's ... visit. ,Tips on how to look and what to ... prime minister and visiting dignitaries along with the special protection group ...
... has commended India for the alacrity with which the ... in the country in the last fortnight. // ... They have told us the quick response of the ... Husbandry) Upma Chowdhury informed reporters. "India's actions have added ...
Other Medicine News:Health News:Concerta, Drug Used in ADHD Treatment Less Likely To Result In Abuse 2Health News:Mind your looks for Bush visit, as world is watching 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: